Biotech Matters podcast

Ep.3 What We're Watching at ASCO 2024

0:00
17:01
Rewind 15 seconds
Fast Forward 15 seconds

As the Bluestar team prepares to head to ASCO 2024 this upcoming weekend, Bluestar Principal Jeff Fineberg sits down with Bluestar Managing Director Erin Olsen to talk about interesting abstracts related to two topics:

  1. What are the unmet needs in 1L therapy?
  2. The KRAS G12C mutation landscape

More episodes from "Biotech Matters"